Nuclea Biotechnologies NanoMolecular DX Purchases Nuclea's Assets for $330K Premium Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay. Nuclea's Former CEO Attempting to Buy Company's Assets in Bankruptcy Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca. Nuclea to Auction Assets as Part of Chapter 7 Bankruptcy Proceedings Premium Set for Jan. 18, 2017, the sale will feature assets including its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer. Nuclea, IRCM Partner to Validate Mass Spec Diabetes Assays Under the partnership the two companies will develop assays for insulin, proinsulin, and c-peptide on clinical sample cohorts at both Nuclea and IRCM's facilities. Nuclea Mass Spec Plans Take Shape with Upcoming Launches of RUO, Clinical Assays Premium The company will focus largely on applying mass spec to relatively established protein markers for which existing immunoassay-based tests have poor performance. Jun 30, 2015 Nuclea, Aelan Ink Biomarker Test, Companion Dx Deal Feb 27, 2015 Nuclea Bio Plans Entry into Clinical Proteomics with Launch of Mass Spec-based Assays in 2015 Premium Jun 6, 2014 Nuclea Inks Collaboration with Thermo Fisher to Develop Mass Spec Assays for Type 2 Diabetes Premium Jun 2, 2014 Nuclea, Thermo Fisher Collaborating on Mass Spec Assays for Type 2 Diabetes Apr 30, 2014 Clinical Reference Lab to Validate Nuclea's Assays Feb 21, 2014 IBL to Become Nuclea Bio's Primary US Distributor for Metastatic Breast Cancer Dx Feb 20, 2014 Foundation Medicine, Quanterix among Omics Firms Getting Massachusetts Tax Incentives Feb 18, 2014 Enzo to Market Nuclea's Metastatic Breast Cancer Dx Sep 9, 2013 Nuclea Biotech Buying Wilex's US Subsidiary Jun 20, 2013 Nuclea, SUNY College to Develop Nanochip for Cancer Diagnosis Jun 19, 2013 Nuclea Biotech, Berkshire Medical Center Collaborate on Prostate, Breast Cancer Biomarker Identification May 7, 2013 Nuclea Biotechnologies Attracts $4.2M in Series D Round Mar 20, 2013 Nuclea, Wilex Partner to Offer Breast Cancer Testing Service Feb 22, 2013 Nuclea Biotechnologies Raises $1.1M Toward $2.5M Financing Round Nov 9, 2012 Nuclea Biotechnologies Expands Office Space, Launches Research Partnership Premium Aug 3, 2012 In Brief This Week: Cepheid; Bruker; Illumina; PerkinElmer; Nuclea Biotechnologies Jul 19, 2012 Nuclea Acquires Tissue Microarray IP Apr 13, 2012 Nuclea Biotechnologies Initiates Series C Round Targeting $10M Mar 12, 2012 Nuclea Partners with Albany VA Institute in Prostate Cancer Marker Study Feb 2, 2012 Nuclea Announces $3.4M in Additional Financing Load More Breaking News In Ongoing False Advertising Suit, Judge Allows Natera Counterclaims Against Guardant Health Centogene Strikes Rare Disease Target Discovery Deal With Insilico Medicine Dilated Cardiomyopathy Gene Mutations Point to Possible Therapeutic Strategy Ginkgo Bioworks Acquires Massachusetts COVID-19 Testing Firm Mainz Biomed Taps DCN Dx to Aid European Study of Enhanced ColoAlert Assay Parse Biosciences Partners With Research Instruments for Southeast Asia Distribution The Scan Transplant Tests Edited Pig Kidneys The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient. UK Changes Some Gene-Edited Crop Rules A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says. Pill Works Against Omicron in Lab Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports. Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.